NCT05413915View on ClinicalTrials.gov

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Myeloid LeukemiaChronic Myeloid Leukemia, BCR/ABL-PositiveChronic Myeloid Leukemia in Remission
Interventions
DRUG

Asciminib

Tyrosine kinase inhibitor

DRUG

Imatinib

Tyrosine kinase inhibitor

Trial Locations (4)

H1T 2M4

Hôpital Maisonneuve-Rosemont (CIUSSS EMTL), Montreal

H3T1E2

Clinical Research Unit - Jewish General Hospital, Montreal

G1J 1Z4

Hôpital Enfant-Jésus - CHUQ, Québec

J1H 5N4

Hôpital Fleurimont - CHUS (CIUSSS Estrie), Sherbrooke

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Sarit Assouline

OTHER